APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatitis B Vaccine (Recombinant)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hepatitis B Vaccine (Recombinant) Market Outlook and Growth Opportunities 2026

2 January 2026197 pages

Choose your research edition.

Industry ResearchHepatitis B Vaccine (Recombinant) Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatitis B Vaccine (Recombinant) Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Hepatitis B Vaccine (Recombinant) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatitis B Vaccine (Recombinant) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatitis B Vaccine (Recombinant) Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Hepatitis B Vaccine (Recombinant) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hepatitis B Vaccine (Recombinant) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hepatitis B Vaccine (Recombinant) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatitis B Vaccine (Recombinant) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hepatitis B Vaccine (Recombinant) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hepatitis B Vaccine (Recombinant) market include GSK, Shenzhen Kangtai Biological Products, Merck, Serum Institute, Sanofi Pasteur, LG Life Sciences, KM Biologics and Dynavax Technologies, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hepatitis B Vaccine (Recombinant) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hepatitis B Vaccine (Recombinant) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hepatitis B Vaccine (Recombinant) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatitis B Vaccine (Recombinant) market size, projected growth trends, production technologies, key applications, and end-use industries.

Hepatitis B Vaccine (Recombinant) Segment by Company

GSK

Shenzhen Kangtai Biological Products

Merck

Serum Institute

Sanofi Pasteur

LG Life Sciences

KM Biologics

Dynavax Technologies

Hepatitis B Vaccine (Recombinant) Segment by Type

10mcg/0.5ml

10mcg/ml

Hepatitis B Vaccine (Recombinant) Segment by Application

Newborn

Adult

Hepatitis B Vaccine (Recombinant) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Hepatitis B Vaccine (Recombinant) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hepatitis B Vaccine (Recombinant) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hepatitis B Vaccine (Recombinant) significant trends, drivers, influence factors in global and regions.

6. To analyze Hepatitis B Vaccine (Recombinant) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis B Vaccine (Recombinant) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatitis B Vaccine (Recombinant) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis B Vaccine (Recombinant).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hepatitis B Vaccine (Recombinant) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hepatitis B Vaccine (Recombinant) industry.

Chapter 3: Detailed analysis of Hepatitis B Vaccine (Recombinant) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hepatitis B Vaccine (Recombinant) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hepatitis B Vaccine (Recombinant) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hepatitis B Vaccine (Recombinant) Industry Trends Table 2. Hepatitis B Vaccine (Recombinant) Industry Drivers Table 3. Hepatitis B Vaccine (Recombinant) Industry Opportunities and Challenges Table 4. Hepatitis B Vaccine (Recombinant) Industry Restraints Table 5. Global Hepatitis B Vaccine (Recombinant) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hepatitis B Vaccine (Recombinant) Revenue Share by Company (2021-2026) Table 7. Global Hepatitis B Vaccine (Recombinant) Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Hepatitis B Vaccine (Recombinant) Sales Volume Share by Company (2021-2026) Table 9. Global Hepatitis B Vaccine (Recombinant) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Hepatitis B Vaccine (Recombinant) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hepatitis B Vaccine (Recombinant) Key Company Manufacturing Base & Headquarters Table 12. Global Hepatitis B Vaccine (Recombinant) Company, Product Type & Application Table 13. Global Hepatitis B Vaccine (Recombinant) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hepatitis B Vaccine (Recombinant) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 10mcg/0.5ml Table 18. Significant Companies of 10mcg/ml Table 19. Global Hepatitis B Vaccine (Recombinant) Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Hepatitis B Vaccine (Recombinant) Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Hepatitis B Vaccine (Recombinant) Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Hepatitis B Vaccine (Recombinant) Sales Volume Share by Type (2021-2026) Table 23. Global Hepatitis B Vaccine (Recombinant) Sales Volume Share by Type (2027-2032) Table 24. Global Hepatitis B Vaccine (Recombinant) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hepatitis B Vaccine (Recombinant) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Hepatitis B Vaccine (Recombinant) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Hepatitis B Vaccine (Recombinant) Sales Value Share by Type (2021-2026) Table 28. Global Hepatitis B Vaccine (Recombinant) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Newborn Table 30. Significant Companies of Adult Table 31. Global Hepatitis B Vaccine (Recombinant) Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 32. Global Hepatitis B Vaccine (Recombinant) Sales Volume by Application (2021-2026) & (W Units) Table 33. Global Hepatitis B Vaccine (Recombinant) Sales Volume by Application (2027-2032) & (W Units) Table 34. Global Hepatitis B Vaccine (Recombinant) Sales Volume Share by Application (2021-2026) Table 35. Global Hepatitis B Vaccine (Recombinant) Sales Volume Share by Application (2027-2032) Table 36. Global Hepatitis B Vaccine (Recombinant) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Hepatitis B Vaccine (Recombinant) Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Hepatitis B Vaccine (Recombinant) Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Hepatitis B Vaccine (Recombinant) Sales Value Share by Application (2021-2026) Table 40. Global Hepatitis B Vaccine (Recombinant) Sales Value Share by Application (2027-2032) Table 41. Global Hepatitis B Vaccine (Recombinant) Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 42. Global Hepatitis B Vaccine (Recombinant) Sales by Region (2021-2026) & (W Units) Table 43. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2021-2026) Table 44. Global Hepatitis B Vaccine (Recombinant) Sales by Region (2027-2032) & (W Units) Table 45. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2027-2032) Table 46. Global Hepatitis B Vaccine (Recombinant) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Hepatitis B Vaccine (Recombinant) Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Hepatitis B Vaccine (Recombinant) Sales Value Share by Region (2021-2026) Table 49. Global Hepatitis B Vaccine (Recombinant) Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Hepatitis B Vaccine (Recombinant) Sales Value Share by Region (2027-2032) Table 51. Global Hepatitis B Vaccine (Recombinant) Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Hepatitis B Vaccine (Recombinant) Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Hepatitis B Vaccine (Recombinant) Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Global Hepatitis B Vaccine (Recombinant) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026) & (W Units) Table 56. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2021-2026) Table 57. Global Hepatitis B Vaccine (Recombinant) Sales by Country (2027-2032) & (W Units) Table 58. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2027-2032) Table 59. Global Hepatitis B Vaccine (Recombinant) Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Hepatitis B Vaccine (Recombinant) Sales Value Market Share by Country (2021-2026) Table 61. Global Hepatitis B Vaccine (Recombinant) Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Hepatitis B Vaccine (Recombinant) Sales Value Market Share by Country (2027-2032) Table 63. GSK Company Information Table 64. GSK Business Overview Table 65. GSK Hepatitis B Vaccine (Recombinant) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. GSK Hepatitis B Vaccine (Recombinant) Product Portfolio Table 67. GSK Recent Development Table 68. Shenzhen Kangtai Biological Products Company Information Table 69. Shenzhen Kangtai Biological Products Business Overview Table 70. Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Product Portfolio Table 72. Shenzhen Kangtai Biological Products Recent Development Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck Hepatitis B Vaccine (Recombinant) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Merck Hepatitis B Vaccine (Recombinant) Product Portfolio Table 77. Merck Recent Development Table 78. Serum Institute Company Information Table 79. Serum Institute Business Overview Table 80. Serum Institute Hepatitis B Vaccine (Recombinant) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Serum Institute Hepatitis B Vaccine (Recombinant) Product Portfolio Table 82. Serum Institute Recent Development Table 83. Sanofi Pasteur Company Information Table 84. Sanofi Pasteur Business Overview Table 85. Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Product Portfolio Table 87. Sanofi Pasteur Recent Development Table 88. LG Life Sciences Company Information Table 89. LG Life Sciences Business Overview Table 90. LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. LG Life Sciences Hepatitis B Vaccine (Recombinant) Product Portfolio Table 92. LG Life Sciences Recent Development Table 93. KM Biologics Company Information Table 94. KM Biologics Business Overview Table 95. KM Biologics Hepatitis B Vaccine (Recombinant) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. KM Biologics Hepatitis B Vaccine (Recombinant) Product Portfolio Table 97. KM Biologics Recent Development Table 98. Dynavax Technologies Company Information Table 99. Dynavax Technologies Business Overview Table 100. Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Dynavax Technologies Hepatitis B Vaccine (Recombinant) Product Portfolio Table 102. Dynavax Technologies Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. Hepatitis B Vaccine (Recombinant) Distributors List Table 106. Hepatitis B Vaccine (Recombinant) Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Hepatitis B Vaccine (Recombinant) Product Image Figure 2. Global Hepatitis B Vaccine (Recombinant) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatitis B Vaccine (Recombinant) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hepatitis B Vaccine (Recombinant) Sales (2021-2032) & (W Units) Figure 5. Global Hepatitis B Vaccine (Recombinant) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Hepatitis B Vaccine (Recombinant) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 10mcg/0.5ml Image Figure 10. 10mcg/ml Image Figure 11. Global Hepatitis B Vaccine (Recombinant) Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Hepatitis B Vaccine (Recombinant) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Hepatitis B Vaccine (Recombinant) Sales Volume Share by Type (2021-2032) Figure 14. Global Hepatitis B Vaccine (Recombinant) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Hepatitis B Vaccine (Recombinant) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Hepatitis B Vaccine (Recombinant) Sales Value Share by Type (2021-2032) Figure 17. Newborn Image Figure 18. Adult Image Figure 19. Global Hepatitis B Vaccine (Recombinant) Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Hepatitis B Vaccine (Recombinant) Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Hepatitis B Vaccine (Recombinant) Sales Volume Share by Application (2021-2032) Figure 22. Global Hepatitis B Vaccine (Recombinant) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Hepatitis B Vaccine (Recombinant) Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Hepatitis B Vaccine (Recombinant) Sales Value Share by Application (2021-2032) Figure 25. Global Hepatitis B Vaccine (Recombinant) Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 26. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Hepatitis B Vaccine (Recombinant) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Hepatitis B Vaccine (Recombinant) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Hepatitis B Vaccine (Recombinant) Sales Value (2021-2032) & (US$ Million) Figure 30. North America Hepatitis B Vaccine (Recombinant) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Hepatitis B Vaccine (Recombinant) Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Hepatitis B Vaccine (Recombinant) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Hepatitis B Vaccine (Recombinant) Sales Value (2021-2032) & (US$ Million) Figure 36. South America Hepatitis B Vaccine (Recombinant) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Hepatitis B Vaccine (Recombinant) Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Hepatitis B Vaccine (Recombinant) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Hepatitis B Vaccine (Recombinant) Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Hepatitis B Vaccine (Recombinant) Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 10mcg/0.5ml
  • 10mcg/ml
Applications
  • Newborn
  • Adult
Companies covered
  • GSK
  • Shenzhen Kangtai Biological Products
  • Merck
  • Serum Institute
  • Sanofi Pasteur
  • LG Life Sciences
  • KM Biologics
  • Dynavax Technologies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hepatitis B Vaccine (Recombinant) Sales Value (2021-2032)
  4. 1.2.2 Global Hepatitis B Vaccine (Recombinant) Sales Volume (2021-2032)
  5. 1.2.3 Global Hepatitis B Vaccine (Recombinant) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hepatitis B Vaccine (Recombinant) Market Dynamics
  1. 2.1 Hepatitis B Vaccine (Recombinant) Industry Trends
  2. 2.2 Hepatitis B Vaccine (Recombinant) Industry Drivers
  3. 2.3 Hepatitis B Vaccine (Recombinant) Industry Opportunities and Challenges
  4. 2.4 Hepatitis B Vaccine (Recombinant) Industry Restraints
3 Hepatitis B Vaccine (Recombinant) Market by Company
  1. 3.1 Global Hepatitis B Vaccine (Recombinant) Company Revenue Ranking in 2025
  2. 3.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Company (2021-2026)
  3. 3.3 Global Hepatitis B Vaccine (Recombinant) Sales Volume by Company (2021-2026)
  4. 3.4 Global Hepatitis B Vaccine (Recombinant) Average Price by Company (2021-2026)
  5. 3.5 Global Hepatitis B Vaccine (Recombinant) Company Ranking (2024-2026)
  6. 3.6 Global Hepatitis B Vaccine (Recombinant) Company Manufacturing Base and Headquarters
  7. 3.7 Global Hepatitis B Vaccine (Recombinant) Company Product Type and Application
  8. 3.8 Global Hepatitis B Vaccine (Recombinant) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hepatitis B Vaccine (Recombinant) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hepatitis B Vaccine (Recombinant) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hepatitis B Vaccine (Recombinant) Market by Type
  1. 4.1 Hepatitis B Vaccine (Recombinant) Type Introduction
  2. 4.1.1 10mcg/0.5ml
  3. 4.1.2 10mcg/ml
  4. 4.2 Global Hepatitis B Vaccine (Recombinant) Sales Volume by Type
  5. 4.2.1 Global Hepatitis B Vaccine (Recombinant) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hepatitis B Vaccine (Recombinant) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Hepatitis B Vaccine (Recombinant) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Hepatitis B Vaccine (Recombinant) Sales Value by Type
  9. 4.3.1 Global Hepatitis B Vaccine (Recombinant) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Hepatitis B Vaccine (Recombinant) Sales Value by Type (2021-2032)
  11. 4.3.3 Global Hepatitis B Vaccine (Recombinant) Sales Value Share by Type (2021-2032)
5 Hepatitis B Vaccine (Recombinant) Market by Application
  1. 5.1 Hepatitis B Vaccine (Recombinant) Application Introduction
  2. 5.1.1 Newborn
  3. 5.1.2 Adult
  4. 5.2 Global Hepatitis B Vaccine (Recombinant) Sales Volume by Application
  5. 5.2.1 Global Hepatitis B Vaccine (Recombinant) Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Hepatitis B Vaccine (Recombinant) Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Hepatitis B Vaccine (Recombinant) Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Hepatitis B Vaccine (Recombinant) Sales Value by Application
  9. 5.3.1 Global Hepatitis B Vaccine (Recombinant) Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Hepatitis B Vaccine (Recombinant) Sales Value by Application (2021-2032)
  11. 5.3.3 Global Hepatitis B Vaccine (Recombinant) Sales Value Share by Application (2021-2032)
6 Hepatitis B Vaccine (Recombinant) Regional Sales and Value Analysis
  1. 6.1 Global Hepatitis B Vaccine (Recombinant) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hepatitis B Vaccine (Recombinant) Sales by Region (2021-2032)
  3. 6.2.1 Global Hepatitis B Vaccine (Recombinant) Sales by Region: 2021-2026
  4. 6.2.2 Global Hepatitis B Vaccine (Recombinant) Sales by Region (2027-2032)
  5. 6.3 Global Hepatitis B Vaccine (Recombinant) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hepatitis B Vaccine (Recombinant) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hepatitis B Vaccine (Recombinant) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hepatitis B Vaccine (Recombinant) Sales Value by Region (2027-2032)
  9. 6.5 Global Hepatitis B Vaccine (Recombinant) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hepatitis B Vaccine (Recombinant) Sales Value (2021-2032)
  12. 6.6.2 North America Hepatitis B Vaccine (Recombinant) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hepatitis B Vaccine (Recombinant) Sales Value (2021-2032)
  15. 6.7.2 Europe Hepatitis B Vaccine (Recombinant) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hepatitis B Vaccine (Recombinant) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hepatitis B Vaccine (Recombinant) Sales Value (2021-2032)
  21. 6.9.2 South America Hepatitis B Vaccine (Recombinant) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hepatitis B Vaccine (Recombinant) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hepatitis B Vaccine (Recombinant) Sales Value Share by Country, 2025 VS 2032
7 Hepatitis B Vaccine (Recombinant) Country-level Sales and Value Analysis
  1. 7.1 Global Hepatitis B Vaccine (Recombinant) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hepatitis B Vaccine (Recombinant) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2032)
  4. 7.3.1 Global Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2026)
  5. 7.3.2 Global Hepatitis B Vaccine (Recombinant) Sales by Country (2027-2032)
  6. 7.4 Global Hepatitis B Vaccine (Recombinant) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hepatitis B Vaccine (Recombinant) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hepatitis B Vaccine (Recombinant) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hepatitis B Vaccine (Recombinant) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hepatitis B Vaccine (Recombinant) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hepatitis B Vaccine (Recombinant) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Hepatitis B Vaccine (Recombinant) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Hepatitis B Vaccine (Recombinant) Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Shenzhen Kangtai Biological Products
  8. 8.2.1 Shenzhen Kangtai Biological Products Company Information
  9. 8.2.2 Shenzhen Kangtai Biological Products Business Overview
  10. 8.2.3 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Product Portfolio
  12. 8.2.5 Shenzhen Kangtai Biological Products Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Hepatitis B Vaccine (Recombinant) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Hepatitis B Vaccine (Recombinant) Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Serum Institute
  20. 8.4.1 Serum Institute Company Information
  21. 8.4.2 Serum Institute Business Overview
  22. 8.4.3 Serum Institute Hepatitis B Vaccine (Recombinant) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Serum Institute Hepatitis B Vaccine (Recombinant) Product Portfolio
  24. 8.4.5 Serum Institute Recent Developments
  25. 8.5 Sanofi Pasteur
  26. 8.5.1 Sanofi Pasteur Company Information
  27. 8.5.2 Sanofi Pasteur Business Overview
  28. 8.5.3 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Product Portfolio
  30. 8.5.5 Sanofi Pasteur Recent Developments
  31. 8.6 LG Life Sciences
  32. 8.6.1 LG Life Sciences Company Information
  33. 8.6.2 LG Life Sciences Business Overview
  34. 8.6.3 LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 LG Life Sciences Hepatitis B Vaccine (Recombinant) Product Portfolio
  36. 8.6.5 LG Life Sciences Recent Developments
  37. 8.7 KM Biologics
  38. 8.7.1 KM Biologics Company Information
  39. 8.7.2 KM Biologics Business Overview
  40. 8.7.3 KM Biologics Hepatitis B Vaccine (Recombinant) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 KM Biologics Hepatitis B Vaccine (Recombinant) Product Portfolio
  42. 8.7.5 KM Biologics Recent Developments
  43. 8.8 Dynavax Technologies
  44. 8.8.1 Dynavax Technologies Company Information
  45. 8.8.2 Dynavax Technologies Business Overview
  46. 8.8.3 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Product Portfolio
  48. 8.8.5 Dynavax Technologies Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hepatitis B Vaccine (Recombinant) Value Chain Analysis
  2. 9.1.1 Hepatitis B Vaccine (Recombinant) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hepatitis B Vaccine (Recombinant) Sales Mode & Process
  6. 9.2 Hepatitis B Vaccine (Recombinant) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hepatitis B Vaccine (Recombinant) Distributors
  9. 9.2.3 Hepatitis B Vaccine (Recombinant) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst